Incannex Healthcare Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS

Ticker Exchange SIC # Website Latest Ticker
IXHL Nasdaq 2833

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Incannex Healthcare Inc

Incannex Healthcare Inc. Quarterly Update, Q1 2024 - Apr 16th, 2024 12:00 pm
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder - Feb 28th, 2024 12:30 pm
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation - Feb 16th, 2024 12:30 pm
Clarion Clinics Open for Psychedelic-Assisted Treatments - Feb 1st, 2024 12:30 pm
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis - Jan 24th, 2024 9:05 pm
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences - Jan 18th, 2024 1:22 pm
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea - Jan 17th, 2024 12:30 pm
Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia - Dec 21st, 2023 9:05 pm
Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea - Dec 6th, 2023 12:30 pm
Incannex Healthcare Announces Completion of its Redomiciliation to the United States - Nov 29th, 2023 6:40 pm
Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC - Nov 16th, 2023 1:30 pm
Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023 - Sep 8th, 2023 11:30 am
Companies Like Incannex Healthcare (ASX:IHL) Are In A Position To Invest In Growth - Sep 6th, 2023 9:21 pm
Incannex preparing psilocybin therapy FDA IND application - Aug 24th, 2023 5:15 pm
Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD - Aug 24th, 2023 11:30 am
Incannex full steam ahead towards sleep apnoea trial - Aug 23rd, 2023 3:45 pm
Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed - Aug 22nd, 2023 11:30 am
Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening - Aug 8th, 2023 12:00 pm
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement - Jul 28th, 2023 11:30 am
Incannex thrilled with positive pre-IND meeting for arthritis treatment - Jul 27th, 2023 5:20 pm